Lexaria Bioscience Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LEXX | 18H0.F | MTVA | LPCN | BDRX | A89.F | |
|---|---|---|---|---|---|---|
| Market cap | 8.57M | 5.11M | 8.83M | 11.87M | 1.41M | 63.00M |
| P/E (TTM) | — | — | — | — | 0.0 | — |
| Forward P/E | -10.4 | — | — | -1.2 | — | — |
| Price/book | 1.4 | -1.1 | 1.3 | 0.5 | 0.0 | -12.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −74.88% | −25.00% | −85.67% | −45.45% | −98.73% | −67.75% |
| Today | +0.99% | −23.81% | +6.35% | −1.37% | −4.61% | −0.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LEXX news ›Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed…
Corxel advances oral GLP-1 therapy with $287m investment
Corxel Pharmaceuticals closed a $287 million Series D1 financing round to support the development of its cardiometabolic drug candidate. The financing round included participation from existing investors RTW Investments and Hengdian Group…
10 Best Natural GLP-1 Alternatives of 2026 Compared by Ingredients And Price
This article was contributed by Buystufz Thorne Berberine 500 is our top pick for a straightforward berberine formula, subject to medical suitability. The best natural GLP-1 supplements offer different approaches to fiber intake, gut…
Lexaria Celebrates its 70th Patent Award
"Our IP is our most valuable asset that, as it grows and strengthens, supports our ongoing and accelerating business development programs," said Richard Christopher, CEO of Lexaria. "Lexaria has built a world-class portfolio of…
SupplySide Global Panelists Outline Product Opportunities Tied to GLP-1 Medication Use
Nutritional Outlook Panelists at SupplySide Global 2026 outlined product opportunities for consumers who are taking, tapering off, or avoiding GLP-1 medications, with protein, fiber, muscle preservation, and suppo
Strategic Development of Complex Oral Therapies
The therapeutic potential of a molecule and its suitability for oral delivery are separate questions. Advances in drug discovery are creating opportunities to address challenging disease targets, but translating those opportunities into…
Post-Bariatric Hypoglycemia Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Post-Bariatric Hypoglycemia Market and Pipeline Appear Robust openPR.com Post-Bariatric Hypoglycemia Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Press release…
5 ways insurance shapes access to GLP-1 weight-loss drugs in 2026
GLP-1 insurance coverage shapes who can afford Wegovy and Zepbound in 2026, from employer plans and Medicare rules to Medicaid and paying out of pocket A prescription for a GLP-1 weight-loss drug answers a medical question. It does not…
Could a diabetes medication be the next wonder drug?
For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health. The findings, published in the Journal of Clinical Investigation, provide new insight into cardiovascular benefits of the drug…
Kirkland and Pinsents line up for diabetes drug battle
Boehringer Ingelheim has instructed a team from Kirkland, while Teva is being represented by Pinsent Masons Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND Copyright © Legal Benchmarking Limited and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com13
- investingnews.com4
- stocktitan.net4
- tradingview.com3
- openpr.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 40 articles, not a forecast.